Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
Sight Sciences reported Q1 revenue of $19.7 million, up 13% year-over-year, driven by growth in both Interventional Glaucoma and Dry Eye segments. The company raised full-year 2026 revenue guidance to $83.0–$89.0 million and announced a final judgment in its patent litigation against Alcon, awarding $55.4 million in past damages and a 10% ongoing royalty.
Key figures
- Revenue
- $19.7 million
- Guidance
- FY2026 revenue $83.0M-$89.0M, raised from $82.0M-$88.0M
- Revenue Yoy
- 13%
- Cash usage
- $7.0 million
- Cash balance
- $85.0 million
- Gross margin
- 86%
- Litigation damages
- $55.4 million
- Litigation royalty rate
- 10%
- Interventional dry eye revenue
- $1.4 million
- Interventional glaucoma revenue
- $18.3 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.